After a long summer break, we continue introducing our work packages of project MOTION.

UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷

@reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social thank you very much for sharing our experience and hosting the annual meeting!

🙌We wrapped up an amazing MOTION annual meeting! 🙌
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.

Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials

👋 After a short break, we continue to introduce our WPs to you👋
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽

💫This week we are introducing WP4 & WP5 💫
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.

🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social

📷More info in the graphic 📷

🎥 Say hi to Work Package 3 of the #MotionProject!

WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡

Watch now & learn more about our mission in hepatology!

#WP3 #LiverResearch #PSVD #ScienceInMotion

🧬 WELCOME to WP3, In this WP we're exploring the molecular & prognostic characterization of PSVD using histology, metabolomics & RNA-seq.

The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.

#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials

🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐

In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD

🔽 Find out more in the video below 📷🔽

🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness.

A step forward in risk assessment!

📊👇More info 📊👇
lnkd.in/du8-FjgE

Some of our Motion team members are currently at #EASL2025 in Amsterdam — proudly representing our deep expertise in liver research and innovation. Come say hi if you're around! 👋

#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent

#Portalhypertension Fans ⬇️

🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025

We congratulate him from the bottom of our #livers 😉 and are incredibly proud!

🌐 MOTION Work Package 2 🌐

WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️

#liver #liverdesease #PortalHypertension #ClinicalTrial

#liver #PortalHypertension #clinicaltrails #cACLD
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....

🌐More info in the video below 🌐 🔽🔽

💬Introducing WP1💬

This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.

🌐Fridays with the MOTION Team = science, smiles & serious vibes 😎🧪
Just something else.... :) 🌐

When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.

#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork

🌟 Our MOTION team is growing – so are our achievements! 🌟

While knowledge is undoubtedly necessary in a project, people form the foundation of success...

Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special

🥳🥳 Proud to announce that another VLSG member Nikolaus Pfisterer has successfully defended his #PhD at @meduniwien.ac.at

🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌

MEET the MOTION Team!
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.

#PortalHypertension Fans !! #liver 👍
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.

⬇️📷More info 📷⬇️

🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver